• Drug: Fylnetra (pegfilgrastim-pbbk)

  • Manufacturer: Amneal Pharmaceuticals

  • Route of Administration: Subcutaneous

  • Site of Care: Outpatient

  • Approved Indication:

    • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
    • to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
  • Disease: neutropenia associated with myelosuppressive anti-cancer therapy, hematopoietic syndrome of acute radiation syndrome

  • Therapeutic Area: Hematology, Oncology

  • Enrollment Form Link: Amneal PATHways

  • Phone Number: 866-4AMNEAL (866-426-6325)
  • Fax Number: 855-690-6573
  • Product Website: fylnetra.com